Atopic Dermatitis Clinical Trial
Official title:
Genetic Screening for Filaggrin Mutation in Atopic Dermatitis and Ichthyosis Vulgaris in the African American Population
The investigators' primary objective is to identify common and rare mutations in the filaggrin gene in African American patients with a diagnosis of atopic dermatitis and ichthyosis vulgaris. Atopic dermatitis, or eczema, is a common, chronic, relapsing and remitting problem in many children and affects 10-20% of the pediatric population. Itch is a predominant feature of this disease and is quite disruptive to daily activities of life. In addition to itch, it is characterized by markedly dry skin, small red bumps that may have fluid. Ichthyosis vulgaris is characterized by extremely dry, scaly skin with a fine white scale and increased amounts of lines noted on the palms. Filaggrin is a protein that is essential for the skin to function properly as a barrier and found to be mutated in some European patients with ichthyosis vulgaris and atopic dermatitis. This association has not been looked at in the African American population. Genomic DNA (gDNA) will be purified from buccal swabs using commercially available kits and analyzed.
Genetic screening and molecular dermatology allow physicians and scientists to screen
populations who manifest a specific genetic disorder of skin, hair or nails and to study
animal models for experiment-induced dermatopathology, diseases, and treatments. The purpose
of such screening is to identify the gene(s) involved in eliciting the phenotypic
characteristics that we as clinicians identify for diagnosis and treatment of said
disease(s).
The field of genetics in dermatology has progressed immensely in the last 20 years and has
strongly influenced the practice of dermatology. Most known single gene disorders, such as
epidermoloysis bullosa, have been mapped to a particular chromosomal region and in many
cases, the causative genes have been identified. However, more common diseases that are
polygenic in origin such as atopic dermatitis remain a challenge to decipher. In addition,
there still remain several monogenic disorders in which the underlying genetic basis is
unclear.
In some cases, genetic analysis can be performed by sequencing entire genes or gene regions,
or screening for specific common mutations. In the Japanese and some of the European
populations, several researchers have been able to find an association between people with
atopic dermatitis and ichythosis vulgaris and the filaggrin gene. Atopic dermatitis, or
ezcema, is a common, chronic, relapsing and remitting problem in many children and affects
10-20% of the pediatric population. Atopic dermatitis is often called the itch that rashes,
since itch is a predominant feature of this disease and is quite disruptive to daily
activities of life. In addition to itch, it is characterized by markedly dry skin, small red
bumps that may have fluid. Though treatments are available to help the rash resolve and to
help with itch, this disease will continue to appear when treatments are stopped and often
become infected.
Ichythosis vulgaris is quite prevalent, an estimated 1 in 250 persons are affected. It is
characterized by extremely dry, scaly skin with a fine white scale and increased amounts of
lines noted on the palms. Ichythosis vulgaris is thought to happen due to a combination of
excess production of one of the layers of the skin and abnormal skin shedding.
Filaggrin is a protein that is essential for the skin to function properly as a barrier. It
was initially thought to be one of the genes responsible for causing atopic dermatitis in
2006 after it was identified as the causal mutation in ichthyosis vulgaris. This association
has been extensively studied in the European population and to a lesser extent in the
Japanese population; however, has not been looked at in the African American population
These new insights may help lead to future targeted therapy for these two extraordinarily
common skin disorders.
General clinical applications of methods for diagnosis may include histological tissue
examination, laboratory-based specimen analysis, and physical examination. However, although
useful, all of these methods are limited to the identification of the phenotypic expression
of the genetic abnormality. Conversely, genetic screening of tissue (collected via buccal
swabs) enables the clinician and scientist to have access to a more finite method of
diagnosis, treatment, and prevention options. Such methods of testing are particularly
appealing for use in disorders in which the exact basis of the disease is unknown, as is the
case of atopic dermatitis and ichythosis vulgaris in the African American population. Thus,
genetic screening in the field of dermatology remains an important research agenda and is
the focus of this proposal. This study allows for the collection of genetic material from
patients seen in the dermatology clinic at Ann & Robert H Lurie Children's Hospital of
Chicago.
;
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05018806 -
Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis
|
Phase 2 | |
Terminated |
NCT03847389 -
Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis
|
Phase 1/Phase 2 | |
Completed |
NCT04090229 -
A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis
|
Phase 1 | |
Active, not recruiting |
NCT05388760 -
Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)
|
Phase 2 | |
Completed |
NCT05530707 -
Evaluation of Acceptability, Skin Barrier Restoration and Balance of Atopic Skin Using Moisturizer
|
N/A | |
Completed |
NCT02595073 -
Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis
|
Phase 3 | |
Recruiting |
NCT05509023 -
Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)
|
Phase 2 | |
Recruiting |
NCT05048056 -
Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT04598269 -
Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis
|
Phase 2 | |
Recruiting |
NCT03936335 -
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
|
||
Withdrawn |
NCT03089476 -
Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy
|
N/A | |
Recruiting |
NCT05029895 -
A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)
|
||
Terminated |
NCT03654755 -
Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT04556461 -
Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function
|
Phase 2 | |
Recruiting |
NCT04818138 -
BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort
|
N/A | |
Completed |
NCT03719742 -
A Clinical Study to Evaluate the Safety and Efficacy of a Baby Cleanser and a Moisturizer
|
N/A | |
Completed |
NCT05375955 -
A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.
|
Phase 2 | |
Completed |
NCT03441568 -
In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control
|
N/A | |
Recruiting |
NCT06366932 -
Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models
|
Phase 4 | |
Completed |
NCT03304470 -
A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis
|
Phase 2 |